Literature DB >> 1655889

Identification of guinea pig eosinophil chemotactic factor of anaphylaxis as leukotriene B4 and 8(S),15(S)-dihydroxy-5,9,11,13(Z,E,Z,E)-eicosatetraenoic acid.

R Sehmi1, O Cromwell, G W Taylor, A B Kay.   

Abstract

We have purified and characterized the guinea pig eosinophil chemotactic factor of anaphylaxis (ECF-A), an activity previously described in diffusates from sensitized lung challenged with specific Ag that appeared to selectively attract eosinophils from mixed leukocyte populations. Time course studies showed that the release of ECF-A from challenged presensitized guinea pig lung fragments closely paralleled the release of immunoreactive leukotriene B4 (iLTB4) and histamine. However, the majority of ECF-A (greater than 80%) and iLTB4 (greater than 79%) was extractable with the lipid fraction from the methanol wash of Sep-Pak-extracted diffusate, whereas histamine remained in the aqueous phase. A comparable neutrophil chemotactic activity was also found in the methanol extracts of the anaphylactic diffusates. By using a combination of HPLC and specific RIA, greater than 60% of ECF-A was attributable to LTB4. A second eosinophil chemotactic activity was also identified and coeluted (on both reverse phase and straight phase HPLC) with the synthetic standard 8(S),15(S)-dihydroxy-5,9,11,13(Z,E,Z,E)eicosatetraenoic acid (8(S),15(S)-diHETE). This was confirmed as 8(S),15(S)-diHETE by gas chromatography-mass spectrometry. Platelet-activating factor and histamine had negligible activity for guinea pig eosinophils, compared with synthetic LTB4 (p less than 0.05, 10(-9) and 10(-8) M; p less than 0.01, 10(-7) to 5 x 10(-6) M). In addition, synthetic 8(S),15(S)-diHETE had 3 times less activity than LTB4 at optimal chemotactic concentrations (10(-6) and 10(-7) M, respectively). Thus, guinea pig ECF-A appears to be largely attributable to lipoxygenase products of arachidonic acid, namely LTB4 and 8(S),15(S)-diHETE. Because guinea pig ECF-A was equally active on neutrophils (greater than 96% purity), it can no longer be considered a selective eosinophil chemoattractant.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655889

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Eosinophils in the 1990s: new perspectives on their role in health and disease.

Authors:  A J Wardlaw
Journal:  Postgrad Med J       Date:  1994-08       Impact factor: 2.401

2.  Effect of a 5-lipoxygenase inhibitor, ZM 230487, on cutaneous allergic inflammation in the guinea-pig.

Authors:  M M Teixeira; P G Hellewell
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

Review 3.  Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid.

Authors:  William S Powell; Joshua Rokach
Journal:  Biochim Biophys Acta       Date:  2014-10-29

4.  5-oxo-ETE induces pulmonary eosinophilia in an integrin-dependent manner in Brown Norway rats.

Authors:  P Stamatiou; Q Hamid; R Taha; W Yu; T B Issekutz; J Rokach; S P Khanapure; W S Powell
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

5.  Eosinophil accumulation induced by human interleukin-8 in the guinea-pig in vivo.

Authors:  P D Collins; V B Weg; L H Faccioli; M L Watson; R Moqbel; T J Williams
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

6.  Identification on receptors for leukotriene B4 expressed on guinea-pig peritoneal eosinophils.

Authors:  R Sehmi; A G Rossi; A B Kay; O Cromwell
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

7.  Investigation of the endogenous chemoattractants involved in 111In-eosinophil accumulation in passive cutaneous anaphylactic reactions in the guinea-pig.

Authors:  V B Weg; M L Watson; L H Faccioli; T J Williams
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

Review 8.  Using guinea pigs in studies relevant to asthma and COPD.

Authors:  Brendan J Canning; Yangling Chou
Journal:  Pulm Pharmacol Ther       Date:  2008-02-02       Impact factor: 3.410

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.